
FDA raises manufacturing concerns for Ultragenyx gene therapy
The US Food and Drug Administration (FDA) has decided not to recommend Ultragenyx Pharmaceutical’s UX111 (ABO-102) AAV gene therapy as a treatment for patients with Sanfilippo syndrome type A (MPS IIIA). In its complete response letter (CRL), the FDA requested that the company provide additional information and improvements related to… Read More














